# Chronic Kidney Disease Prognosis Consortium

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2022 · $708,858

## Abstract

PROJECT SUMMARY/ABSTRACT
 Chronic kidney disease (CKD) is a global public health epidemic, affecting 10-16% of the adult population
in Asia, Europe, and North America. The clinical impact of CKD is substantial: risks of end stage renal disease
(ESRD), cardiovascular disease (CVD), and premature mortality are all heightened, but options for CKD
prevention and treatment remain limited.
 The proposed study is a renewal of R01 DK100446, a grant which funds the CKD Prognosis Consortium
(CKD-PC). CKD-PC was formed in 2009 and now includes data on >11 million participants from more than 70
cohorts spanning 40 countries with a strong track record of producing high impact meta-analyses (2 in NEJM,
3 in Lancet, 4 in JAMA, 1 in BMJ, 4 in Kidney Int, 2 in JASN, 2 in AJKD, and 1 in Lancet Diabetes Endocrinol).
CKD-PC complements established cohorts in CKD by representing a broad range of global populations;
spanning the full range of kidney function; devoting tenacious attention to harmonization, exploration of
heterogeneity, and calibration; and meta-analyzing results where appropriate.
 In this new funding period, we will continue to mentor and recruit investigators and cohorts from around the
world, grow substantially, and innovate with new areas of emphasis in the following aims:
Aim 1. To determine risk of incident CKD and CKD progression associated with clinical markers across a
range of patient populations.
Aim 2. To evaluate the risk of non-kidney outcomes associated with eGFR and albuminuria.
Aim 3. To develop risk calculators for CKD incidence, CKD progression, and ESRD overall and in specific
populations such as patients with heart failure.
 In all aims, we will continue to implement and expand upon our innovative meta-analysis methods,
including Markov processes, simulations, and standard incorporation of competing risks. We remain flexible
and efficient in responding to high priority topics set forth by guideline organizations (e.g., Kidney Disease:
Improving Global Outcomes), regulatory agencies (e.g., US Food and Drug Administration) and major societies
(e.g., International Society of Nephrology, National Kidney Foundation, and American Society of Nephrology)
as well as informing global health metrics and economic efforts (e.g., Institute for Health Metrics and
Evaluation Global Burden of Disease). Our overarching goal is to advance the understanding, care, and
outcomes of CKD patients and global populations, using an investigator-led global consortium and the data
and expertise from ~300 international collaborators.

## Key facts

- **NIH application ID:** 10372976
- **Project number:** 5R01DK100446-09
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** JOSEF CORESH
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $708,858
- **Award type:** 5
- **Project period:** 2014-03-28 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10372976

## Citation

> US National Institutes of Health, RePORTER application 10372976, Chronic Kidney Disease Prognosis Consortium (5R01DK100446-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10372976. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*